Skinvisible, Inc.
SKVI
Other OTC0.21
USD
+0.01
- -
CIK
0001085277
ISIN
US8307032032
CUSIP
830703203
Return %
Stock
S&P500
1Y
25.65
26.53
3Y
165.75
76.60
5Y
195.28
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Terry H. Howlett
- Full Time Employees
- 2
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 6320 South Sandhill Road Las Vegas NV United States of America 89120
- IPO Date
- Jan 11, 1999
- CIK
- 0001085277
- Website
- skinvisible.com
- Similar Companies
- Business
- Skinvisible, Inc. Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a research and development company specializing in advanced polymer-based drug delivery technologies for topical, transdermal, and mucosal applications in pharmaceutical, over-the-counter, skincare, cosmetic, and emerging non-dermatological markets including obesity, glucose management, pain relief, and women's health; its flagship Invisicare platform, protected by patents and trade secrets, enhances active ingredient delivery by improving skin adherence, extending duration, sustaining release, and enabling water-based formulations without alcohol, silicones, or organic solvents. The company offers an extensive portfolio of Invisicare-enhanced formulations such as acne treatments (adapalene, clindamycin, retinoic acid, salicylic acid), actinic keratosis and warts therapies (imiquimod), broad-spectrum sunscreens (avobenzone/octocrylene/octinoxate, Tinosorb S with 80-minute water resistance and 8-hour photostability), analgesics and anti-inflammatories (ibuprofen, pramoxine, hydrocortisone, menthol, trolamine salicylate), anti-aging and skin whiteners (hydroquinone, ectoin, peptides, hyaluronic acid, onion bulb for scars/stretch marks), antifungals (naftifine, terbinafine, clotrimazole), antimicrobials and hand sanitizers (chlorhexidine gluconate, triclosan, benzalkonium chloride), dermatitis and moisturizers (urea, non-steroidal atopic creams, allantoin), and pre-surgical preparations, with products out-licensed globally via strategic partnerships generating royalty streams. Founded in 1998 and headquartered at 6320 South Sandhill Road, Suite 9, Las Vegas, Nevada, Skinvisible operates primarily in the United States while pursuing international licensing opportunities. Recent developments include expanded patent applications and provisional filings in 2024 for Invisicare-enabled transdermal delivery of obesity treatments such as GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors achieving up to 99.6% penetration as a needle-free alternative to injections; breakthrough data announcements on 69% drug penetration for obesity formulations; strengthened strategic alliance with Ovation Science incorporating cannabinoid delivery for obesity; significant progress reported in February 2024 on licensee Quoin Pharmaceuticals' (NASDAQ: QNRX) Phase 3 clinical trials of QRX003 for Netherton's syndrome, a rare skin disease nearing potential FDA approval; and active pursuit of additional pharmaceutical and biotech partnerships for commercialization across dermatology, metabolic diseases, and beyond.
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome